Whitehawk Therapeutics (WHWK) Operating Expenses (2010 - 2026)

Whitehawk Therapeutics (WHWK) has 17 years of Operating Expenses data on file, last reported at $23.5 million in Q1 2026.

• On a quarterly basis, Operating Expenses rose 5.18% year-over-year to $23.5 million in Q1 2026; TTM through Mar 2026 was $122.7 million, a 34.93% increase from a year earlier, with the FY2025 full-year figure at $121.5 million, up 30.08% from the prior year.
• Operating Expenses for Q1 2026 stood at $23.5 million, down from $24.9 million in the prior quarter.
• Over the last five years, Operating Expenses for WHWK reached as high as $54.7 million in Q2 2025 and fell as low as $16.1 million in Q1 2022.
• Historically, Operating Expenses has averaged $24.3 million across 5 years, with a median of $22.7 million in 2023.
• On a YoY basis, Operating Expenses climbed as much as 462.5% in 2022 and fell as far as 77.92% in 2022.
• Year by year, Operating Expenses stood at $20.7 million in 2022, then climbed by 16.14% to $24.0 million in 2023, then increased by 8.94% to $26.2 million in 2024, then decreased by 4.97% to $24.9 million in 2025, then decreased by 5.48% to $23.5 million in 2026.
• Per Business Quant data, the three most recent Operating Expenses figures were $23.5 million in Q1 2026, $24.9 million in Q4 2025, and $19.5 million in Q3 2025.